Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | FECH | P22830 | 1/20 | 0.39 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30576048 | 0.91 | ERBB2 (0.50) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL30575894 | 0.91 | ERBB2 (0.50) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25998954 | 0.91 | ERBB2 (0.50) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25432729 | 0.91 | ERBB2 (0.50) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL30576054 | 0.91 | ERBB2 (0.50) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25431255 | 0.91 | ERBB2 (0.50) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL31475892 | 0.88 | EGFR (0.49) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL31476018 | 0.86 | EGFR (0.42) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25430186 | 0.84 | EGFR (0.39) | EGFRERBB2MAP4K4NQO2FECH | |
| SCHEMBL30575932 | 0.84 | EGFR (0.39) | EGFRERBB2MAP4K4NQO2FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885MAP4K4 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.